Cell death induced by tamoxifen in human blood lymphocytes cultivated *in vitro*

Naila Francis Paulo de Oliveira^{*}, Selma Candelária Genari and Heidi Dolder

Instituto de Biologia, Departamento de Biologia Celular, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, Rua Monteiro Lobato, 255, 13083-862, Campinas, São Paulo, Brazil. *Author for correspondence. Email: naila_francis@yahoo.com.br

ABSTRACT. Many chemotherapeutic agents with a potential against solid tumors or leukemia can cause lymphopenia. Tamoxifen (TAM) is a synthetic non-steroidal anti-estrogen drug employed in female breast cancer treatment. The present study investigated the capacity of TAM to induce cell death in human lymphocytes cultivated in vitro. Lymphocytes were obtained from young (25-30 years; n = 3) and elderly women (58-77 years; n = 3) and cultivated for 24 or 48h, with or without TAM (20 μ M). After the culture, cell viability, immunocytochemical response and ultrastructure were evaluated. TAM affected lymphocytes in a time- dependent manner, and cells obtained from elderly women were the most sensitive to TAM. Immunocytochemical analysis evidenced higher frequency of apoptosis in treated cells, and the ultrastructural study revealed autophagic vacuoles, differing from the controls. In summary, the treated lymphocytes were affected by TAM, leading to cell death by apoptosis and autophagy.

Key words: apoptosis, autophagy, chemotherapeutic, cytotoxicity, morphology, ultrastructure.

RESUMO. Morte celular induzida pelo tamoxifeno em linfócitos humanos cultivados *in vitro.* Muitos agentes quimioterápicos com potencial contra tumores sólidos ou leucemias podem causar linfopenia. O Tamoxifeno (TAM) é um agente antiestrógeno não-esteroidal empregado no tratamento de câncer de mama feminino. O presente trabalho investigou a capacidade do TAM em induzir morte celular em linfócitos humanos cultivados *in vitro.* Os linfócitos foram obtidos de mulheres jovens (25-30 anos; n = 3) e idosas (58-77 anos; n = 3) e cultivados por 24 ou 48h, com ou sem TAM (20 μ M). Após a cultura, foram analisadas a viabilidade celular, a resposta imunocitoquímica e a ultraestrutura. Os resultados indicam que o Tamoxifeno induziu morte celular em linfócitos de ambos os grupos, entretanto, as células das mulheres idosas apresentaram-se mais sensíveis ao tratamento. A análise imunocitoquímica mostrou maior frequência de apoptose nas células tratadas e o estudo ultraestrutural revelou vacúolos autofágicos nos linfócitos expostos ao Tamoxifeno. Em conclusão, nosso estudo revelou que o TAM induziu morte celular por apoptose e autofagia.

Palavras-chave: apoptose, autofagia, quimioterápico, citotoxicidade, morfologia, ultraestrutura.

Introduction

Some drugs have a chemotherapeutic potential in relation to tumors or leukemia, due to reduced cell proliferation and a higher cell death rate. However many of these agents, despite their therapeutic potential, can also present severe cytotoxic effects in normal tissues, which lead to side effects observed during chemotherapy, such as mucositis, hair loss, myelosuppression. Moreover, chemotherapy can induce acute lymphopenia and chronic depletion of CDT 4 cells, resulting in a higher susceptibility to opportunistic infections (STAHNKE et al., 2001). In addition, these side effects seem to be more severe in the elderly patient population (BALDUCCI; CORCORAN, 2000; LICHTMAN; VILANI, 2000). Tamoxifen (TAM) ((Z)-1-[4-[2(dimetilaminoetoxi] fenil]-1,2-difenil1-buteno) is a synthetic non- steroidal anti-estrogenic drug widely used as a breast cancer chemotherapy drug for more than 30 years. Nevertheless, TAM is not only an anti-estrogenic agent, because it also has estrogenic properties, depending on the species, tissue and gene considered (OSBORNE et al., 2000). Recent studies indicated that the estrogenic action of TAM can cause endometrial cancer as a serious side effect in postmenopausal patients (AYCART et al., 2005; SHAHI et al., 2008). In pre-menopausal patients, some effects are similar to menopausal symptoms (CLEMONS et al., 2002; NYSTEDT et al., 2003). White (2003) stated that the low dose of tamoxifen used therapeutically in women, can be associated to a possible risk of liver cancers. Tamoxifen can also cause damage to the eyes (OMOTI; OMOTI, 2006; BAGET-BERNALDIZ et al., 2008).

This drug also has been indicated as an agent that induces chromosome aberrations in several cell types (SARGENT et al., 1996; STYLES et al., 1997; MIZUTANI et al., 2004), hepatotoxicity in animals (HARD et al., 1993; ALBUKHARI et al., 2009) and mutations in the lac I gene in transgenic rat livers (STYLES et al., 2001). Some studies also suggested that TAM can lead to DNA damage in many animal organs (DAVIS et al., 1998; CARTHEW et al., 2001) and in human leukocytes, both in vivo (HEMMINKI al., 1997) et and in vitro (HEMMINKI et al., 1995; WOZNIAK et al., 2007). In addition, in vitro studies indicated that tamoxifen enhances the apoptotic effect of cisplatin on primary endometrial cell culture (DRUCKER et al., 2003).

Tamoxifen in micromolar concentrations presents cytotoxic activity not mediated by estrogen receptors in some tumoral and non tumoral cell types, including blood cells, such as neutrophils (JAN et al., 2000). Studies using spleen cell culture pointed out that TAM caused the suppression of lymphocyte mitogenesis, indicating that TAM can be an immunosuppressive agent (BARAL et al., 2000).

Based on the these facts, this study was undertaken to investigate the capacity of TAM to induce cell death in human lymphocytes cultivated *in vitro*, as well as the early ultrastructural modifications involved in this process.

Material and methods

Cells

Lymphocytes were obtained from samples of peripheral blood, obtained by venipuncture with an anticoagulant (EDTA) added. Three volunteers for each group of women (group A = 25-30 years old (n = 3) and group B = 58-77 years old (n = 3)) were used (project approved by Ethics in Research Committee of the Medical Sciences College /UNICAMP). Twenty milliliters of blood sample were centrifuged in a conical centrifuge tube for 15 minutes (1,300 g) to deposit erythrocytes. The interface between plasma and erythrocytes was carefully transferred using a pipette into another centrifuge tube with as few erythrocytes as possible, and centrifuged in a Percoll density gradient (Amersham Pharmacia Biotech) for 30 minutes (660 g), to separate blood cell types. The layer containing mononuclear cells (Percoll-50%-density: 1.06-1.08 g mL⁻¹) was washed twice in Hanks Solution to remove Percoll. These cells were ressuspended in RPMI 1640 medium containing antibiotics (streptomycin 10 mg L⁻¹ and penicillin 1000U L⁻¹) and 10% fetal bovine serum (FBS) (Nutricell,

Campinas State São Paulo) and incubated at 37° C for 2 hours, for monocyte adhesion. Cells in the supernatant were diluted to 4.5×10^5 lymphocytes mL⁻¹, and placed in 25 cm³ tissue culture flasks at 37° C.

Tamoxifen

TAM (Sigma) was dissolved in dimethilsulfoxide (DMSO) (Sigma), followed by an appropriate dilution in RPMI 1640, containing 10% (FBS) with a final concentration of 20 µM in the culture. Similar concentrations of DMSO diluted in RPMI were added to the control cultures. All cultures were maintained for 24 or 48 hours. The solvent concentration (DMSO) was less than 0.1%, which does not affect cell viability (BARAL et al., 2000). The concentration of TAM applied was based on previous studies, which revealed the cytotoxicity of this drug even in micro molar concentrations (JAN et al., 2000; MANDLEKAR; KONG, 2001; MAJUMDAR et al., 2001). The treatment period was limited to 24 and 48 hours because primary cell cultures tend to enter a process of cell death over a longer period, which could lead to not-specific phenotypic alterations.

Cell Viability

The viable cell count for all samples was obtained by the exclusion test of intact cells, by using 1% Trypan Blue and establishing the percentage of unstained alive cells for the total of ressuspended cells. Cell viability was analyzed after 24 or 48 hours of culture, and counted in a hemocytometer chamber.

Apoptosis Detection

Following the manufacturer's protocol (Oncogene Research Products-Annexin V-Biotin Apoptosis Detection Kit), cells were incubated with annexin-biotin that presents a high affinity for phosphatidylserine, followed by incubation with FITC-conjugated anti-biotin. This procedure was employed to target apoptotic cells that express phosphatidylserine (PS) on the outer leaflet of the plasma membrane. The preparations were analyzed with a Zeiss Axioskop fluorescence microscope equipped with a set of filters for fluorescein. A total of 400 cells were counted for each sample, using low magnification to show a larger number of cells. The number of apoptotic cells from each blood sample was established based on the fluorescent tagging observed with the microscope.

Cell death induced by tamoxifen

Transmission electron microscopy

The cultured cells were deposited in a pellet by centrifugation, and washed in 0.1 M cacodylate buffer (pH 7.2), with 1.5% saccharose. Cells were fixed in 2.5% glutaraldehyde, 1.25% formaldehyde and 0.03% picric acid solution in 0.1 M cacodylate buffer (pH 7.2), with 1.5% saccharose for 1 hour at room temperature. The fixed cells were washed three times in the same buffer, post-fixed in 1% osmium tetroxide in the same buffer for 1 hour, and washed three times in distilled water. Then, the cells were included in 2% agar, dehydrated with a graded series of acetone solutions, and embedded in Epon. Thin sections of selected areas of the epoxy block were cut with an ultramicrotome using a diamond knife. Sections were mounted on copper grids, stained with alcoholic uranyl acetate and lead citrate, and examined with a Zeiss Leo 906 transmission electron microscope at an accelerating voltage of 60 KV (modified from MATOS et al., 1995).

Statistical Analysis

Statistical analysis was performed using One-Way ANOVA with Tukey's test, considering values of p < 0.05 as statistically significant. Data are presented in graphs as mean values \pm sd.

Results

Cell Viability

Statistic analysis indicated a significant difference in cell viability between treated cells and controls. A reduced viability was observed in treated cells from both young and elderly women (Figure 1). Meantime, this occurred after 48 hours contact for young women (group A), while in group B it was significant already after 24 hours. Also, the viability of group B cells was lower than group A in all studied conditions.

Apoptosis Detection

According to Figure 2, the percentage of apoptotic cells, identified by FITC-conjugated biotin, was higher in treated cultures comparing to respective controls, in both groups. We noticed that the group A presented a small increase of cells undergoing apoptosis, when control and treated cells were compared after 24 hours, but after 48 hours, this number was significantly higher. Moreover, group B presented a higher percentage of apoptotic cells, in both treated cultures and controls, when compared to group A, but significant differences were not found for treated cells, when comparing the two culture periods.



Figure 1. Cell viability of human lymphocytes cultivated *in vitro*, verified by Trypan Blue. Exclusion Test. C = control, T = treatment, A = young women (n = 3), B = elderly women (n = 3), 24 and 48 hours. The comparison between treatments and groups were made through One-Way ANOVA, followed by Tukey's test, with a significance level of 5%. Data are presented as mean values \pm sd. Significant differences are identified by \star (comparisons between the treatments within group A) and \bullet (comparison between the treatments within group B).



Figure 2. Frequency of apoptosis in human lymphocytes cultivated *in vitro*, verified by fluorescent marking of phosphatidylserine on the outer leaflet of the cell membrane. C = control, T = treatment, A = young women (n = 3), B = elderly women (n = 3), 24 and 48 hours. 400 cells were counted for each sample. The comparison between treatments and groups were made through One-Way ANOVA, followed by Tukey's test, with a significant differences are represented as mean values \pm sd. Significant differences are represented by \star (comparison between treatments within group A) and \bullet (comparison between treatments within group B).

Transmission Electron Microscopy

In thin sections of control lymphocytes (Figure 3A and C), spherical cells were observed containing a large nucleus with a pattern of condensed and loose chromatin, occupying most of the cell volume. The membranes are well preserved and, although the cells have only a thin layer of cytoplasm, they also contain many mitochondria and ribosomes. The treatment with TAM revealed cells with a nucleus with the same condensed and loose chromatin pattern, decreased cell volume, but more organelles are present. Endoplasmic reticulum, a small Golgi complex and some large cytoplasmic vacuoles were found, which possibly represent autophagic vacuoles, as suggested by the membranous whorls within the vacuoles (Figure 3B and D). Notice that, in these cells (Figure 3B and D), the membranes are well preserved but there are fewer microvilli. We can also observe that after 48 hours of treatment with TAM, there was a loss of the typical spherical cell shape as well as of microvilli, and the flattened nucleus has superficial depressions (Figure 3D).



Figure 3. (A) Typical control lymphocyte, maintained for 24h in culture: spherical cells are found containing a large nucleus (n), with condensed and loose chromatin pattern, scant cytoplasm and mitochondria (m) (x 14,500); (B) Lymphocyte treated with 20 μ M of TAM for 24h: the typical cell is spherical, a typical nucleus (n), autophagic-like vacuoles (a) and mitochondria (m) (x 16,500); (C) Control lymphocyte maintained for 48h in culture: cell is spherical, with a typical nucleus, scant cytoplasm and mitochondria (m) (x 15,000); (D) Lymphocyte treated with 20 μ M of TAM for 48h, a group in which almost all cells have lost their spherical shape. The nucleus (n) is also not spherical, with superficial depressions, although the chromatin pattern still has condensed and loose areas; mitochondria (m) and autophagic-like vacuoles, one containing membrane whorls, which may be a degenerating mitochondrium (a) (x 16,500).

Discussion

Tamoxifen has been clinically used as a chemotherapeutic drug against breast cancer, and its potential to induce cell death in various cell types is still unclear. The present study is the first to show the morphological aspects of TAM-induced cell death in human lymphocytes cultivated *in vitro*.

The higher apoptosis rates observed in treated cultures are consistent with previous studies, which affirm that lymphoid cells can undergo apoptosis in response to a variety of stimuli, including chemotherapeutic drugs (FRIESEN et al., 1996). Moreover TAM is cytotoxic at micromolar concentrations (JAN et al., 2000; MANDLEKAR; KONG, 2001), also affecting non breast cancer cells (MAJUMDAR et al., 2001; PETINARI et al., 2004; KIM et al., 2007; GIL-SALÚ et al., 2008). The lower percentage of viable cells and the higher frequency of apoptosis in lymphocytes obtained from elderly women can be associated with the aging of the immune system, which is in functional decline (GRUBECK-LOEBENSTEIN et al., 1998), resulting in a dramatic reduction of responsiveness as well as functional deregulation. Some authors evidenced that lymphocytes of aged persons are more prone to undergo apoptosis, in comparison to lymphocytes of younger people (PAGLIARA et al., 2003). As previously documented, elderly patients are especially prone to increased toxicity due to morbidity and aged physiology. Chemotherapy may have such a strong effect on aged patients that some authors suggested the investigation of multiple organs should be carried out before treatment (SAWHNEY et al., 2005).

Although the data that refers to translocation of PS is consistent with apoptosis, our ultrastructural results are more compatible with autophagy. The large cytoplasmic vacuoles, which are probably autophagic vacuoles, are present only in the treated lymphocytes. This mode of cell death is characterized by massive degradation of cell contents, which includes essential organelles such as mitochondria, by means of complex intracellular membrane vesicle reorganization and lysosomal activity (WANG; KLIONSKY, 2003; GOZUACIK; KIMCHI, 2004). The diminished number of microvilli in treated cells suggests an effort to reduce the cell membrane area in contact with TAM. Previous studies have also shown that Tamoxifen induces signs of autophagy in breast cancer cells and non-breast cancer cells (KLIONSKY et al., 2003; QADIR et al., 2008). Autophagy has been observed

in cells treated with chemotherapeutic drugs other than TAM (KONDO; KONDO, 2006; MORETTI et al., 2007). Some authors showed that apoptosis and autophagy can occur in parallel, as seen in studies with malignant glioma cells, breast cancer cells and neurons (DAIDO et al., 2004; LAMPARSKA-PRZYBYSZ et al., 2005; MATYJA et al., 2005). Moreover, other studies indicate that accumulation of autophagic vacuoles can precede apoptotic cell death (CUI et al., 2007; WANG et al., 2007; OGATA et al., 2008). Recent studies have shown results similar to our observations. In those studies it was demonstrated that, in tumoral lineages with PS translocation, autophagosomes were identified. Previous studies already showed that PS translocation is not an exclusive characteristic of apoptotic cell death, and can be found in necrosis (LECOEUR et al., 2001; KRYSKO et al., 2004). Our data does not present specific ultrastructural aspects of apoptosis, perhaps because culture was restricted to 24-48 hours, and characteristics such as chromatin alterations require a longer period to become ultrastructurally identifiable. However, we observed cells that express phosphatidylserine (PS) on the outer leaflet of the plasma membrane, one of the most important early molecular modifications that can indicate apoptosis (AMARANTE-MENDES; GREEN, 1999).

Based on these results, we may conclude that lymphocytes treated with tamoxifen demonstrated lower cell viability as well as a higher cell death rate than their controls. Also, longer periods of treatment with TAM lead to more affected cells and more morphological changes. Besides that, lymphocytes obtained from elderly women are more likely to undergo apoptosis, in both control and treated cultures. Our data also suggests that apoptosis and autophagic cell death may be parallel events.

References

ALBUKHARI, A. A.; GASHLANA, H. M.; EL-BESHBISHYB, H. A.; NAGYC, A. A.; ABDEL-NAIM, A. B. Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats. **Food and Chemical Toxicology**, v. 47, n. 7, p. 1689-1695, 2009.

AMARANTE-MENDES, G. P.; GREEN, D. R. The regulation of apoptotic cell death. **Brazilian Journal of Medical and Biological Research**, v. 32, n. 9, p. 1053-1061, 1999.

AYCART, J. B.; PÉREZ, I. S.; MARTÍN, T. R; VILLAESCUSA, G.; ANDRADE, M. C. G. Sarcomas de útero después de tratamiento con tamoxifeno por cáncer de mama. **Oncología**, v. 28, n. 7, p. 38-42, 2005.

BAGET-BERNALDIZ, M.; SOLER LLUIS, N.; ROMERO-AROCA, P.; TRAVESET-MAESO, A. Maculopatía por tamoxifeno: Estudio mediante la tomografía de coherencia óptica/ Optical coherence tomography study in tamoxifen maculopathy. **Archivos de la Sociedad Española de Oftalmologia**, v. 83, n. 10, p. 615-617, 2008.

BALDUCCI, L.; CORCORAN, M. Antineoplastic chemotherapy of the older patient. **Hematology**/ **oncology clinics of North America**, v. 14, n. 1, p. 193-212, 2000.

BARAL, E.; NAGY, E.; KWOK, S.; MCNICOL, A.; GERRARD, J.; BERCZI, I. Supression of lymphocytes mitogenesis by tamoxifen: studies on protein kinase C, calmodulin and calcium. **Neuroimmunomodulation**, v. 7, n. 2, p. 68-76, 2000.

CARTHEW, P.; LEE, P. N.; EDWARDS, R. E.; HEYDON, R. T.; NOLAN, B. M.; MARTIN, E. A Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. **Archives of Toxicology**, v. 75, n. 6, p. 375-380, 2001.

CLEMONS, M.; DANSON, S.; HOWELL, A. Tamoxifen (Nolvadex): a review. **Cancer Treatment Reviews**, v. 28, n. 4, p. 165-180, 2002.

CUI, Q.; TASHIRO, S.; ONODERA, S.; MINAMI, M.; IKEJIMA, T. Autophagy preceded apoptosis in oridonintreated human breast cancer MCF-7 cells. **Biological and Pharmaceutical Bulletin**, v. 30, n. 5, p. 859-864, 2007.

DAIDO, S.; KANZAWA, T.; YAMAMOTO, A.; TAKEUCHI, H.; KONDO, Y.; KONDO, S. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. **Cancer Research**, v. 64, n. 12, p. 4286-4293, 2004.

DAVIS, W.; VENITT, S.; PHILLIPS, D. H. The metabolic activation of tamoxifen and a-hydroxytamoxifen to DNAbinding species in rat hepatocytes proceeds via sulphation. **Carcinogenesis**, v. 19, n. 5, p. 861-866, 1998.

DRUCKER, L.; STACKIEVICZ, R.; RADNAY, J.; SHAPIRA, H.; COHEN, I.; YARKONI, S. Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures. **Anticancer Research**, v. 23, n. 2, p. 1549-1554, 2003.

FRIESEN, C.; HERR, I.; KRAMMER, P. H.; DEBATIN, K. M. Involvement of the CD95 (APO-1/FAZ) receptor/ligand system in drug-induced apoptosis in leukemia cells. **Nature Medicine**, v. 2, n. 5, p. 574-577, 1996.

GIL-SALÚ, J. L.; BOSCO-LÓPEZ, J.; DOMÍNGUEZ-VILLAR, M.; DOMÍNGUEZ-PASCUAL, I.; PÉREZ-REQUENA, J.; PALOMO, M. J.; LÓPEZ-ESCOBAR, M. Ensayos de quimiosensibilidad en cultivos primarios de tumores cerebrales. **Neurocirugía**, v. 19, n. 1, p. 5-10, 2008. GOZUACIK, D.; KIMCHI, A. Autophagy as a cell death and tumor suppressor mechanism. **Oncogene**, v. 12, n. 23, p. 2891-2906, 2004.

GRUBECK-LOEBENSTEIN, B.; BERGER, P.; SAURWEIN-TEISSL, M.; ZISTERER, K.; WICK, G. No immunity for the elderly. **Nature Medicine**, v. 4, n. 8, p. 870, 1998.

HARD, G. C.; IANTROPOULOS, M. J.; JORDA, K.; KATENBERGER, O. P.; IMONDI, A. R.; WILLIAMS, G. M. Major differences in the hepatocarcinogenecity and DNA adduct forming ability between toremofene and tamoxifen in female Crl: CD(BR) rats. **Cancer Research**, v. 53, n. 19, p. 4534-4541, 1993.

HEMMINKI, K.; WIDLACK, P.; HOU, S. M. DNA adducts caused by tamoxifen and toremifene in human microssomal system and lymphocytes *in vitro*. **Carcinogenesis**, v. 16, n. 7, p. 1661-1664, 1995.

HEMMINKI, K.; RAJANIEMI, H.; KOSKINEN, M.; HANSOON, J. Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients. **Carcinogenesis**, v. 18, n. 1, p. 9-13, 1997.

JAN, C. R.; CHENG, J. S.; CHOU, K. J.; WANG, S. P.; LEE, K. C.; TANG, K. Y.; TSENG, L. L.; CHIANG, H. T. Dual effect of tamoxifen, an anti-breast-cancer drug, on intracellular Ca^{2+} and cytotoxicity in intact cells. **Toxicology and Applied Pharmacology**, v. 168, n. 1, p. 58-63, 2000.

KIM, H. S.; ISHIZAKA, M.; KAZUSAKA, A.; FUJITA, S. Di-(2-ethylhexyl) phthalate suppresses tamoxifeninduced apoptosis in GH3 pituitary cells. **Archives of Toxicology**, v. 81, n. 1, p. 27-33, 2007.

KLIONSKY, D. J.; CREGG, J. M.; DUNN, W. A.; EMR JR., S. D.; SAKAI, Y.; SANDOVAL, I. V.; SIBIRNY, A.; SUBRAMANI, S.; THUMM, M.; VEENHUIS, M.; OHSUMI, Y. A unified nomenclature for yeast autophagy-related genes. **Developmental Cell**, v. 5, n. 4, p. 539-545, 2003.

KONDO, Y.; KONDO, S. Autophagy and cancer therapy. **Autophagy**, v. 2, n. 2, p. 85-90, 2006.

KRYSKO, O.; DE RIDDER, L.; CORNELISSEN, M. Phosphatidylserine exposure during early primary necrosis (oncosis) in JB6 cells as evidenced by immunogold labeling technique. **Apoptosis**, v. 9, n. 4, p. 495-500, 2004.

LAMPARSKA-PRZYBYSZ, M.; GAJKOWSKA, B.; MOTYL, T. Cathepsins and BID are involved in the molecular switch between apoptosis and autophagy in breast cancer MCF-7 cells exposed to camptothecin. **Journal of Physiology and Pharmacology**, v. 56, n. 3, p. 159-179, 2005.

LECOEUR, H.; PREVOST, M. C.; GOUGEON, M. L. Oncosis is associated with exposure of phosphatidylserine residues on the outside layer of the plasma membrane: A reconsideration of the specificity of the annexin V/propidium iodide assay. **Cytometry**, v. 44, n. 1, p. 65-72, 2001.

LICHTMAN, S. M.; VILANI, G. Chemotherapy in the elderly: pharmacological considerations. **Cancer Control**, v. 7, n. 6, p. 548-556, 2000.

MAJUMDAR, S. K.; VALDELLON, J. A.; BROWN, K. A. *In vitro* investigation on the toxicity and cell death induced by tamoxifen on two non-breast cancer cell types. **Journal of Biomedicine & Biotechnology**, v. 1, n. 3, p. 99-107, 2001.

MANDLEKAR, S.; KONG, A. N. Mechanism of tamoxifen-induced apoptosis. **Apoptosis**, v. 6, n. 6, p. 469-477, 2001.

Cell death induced by tamoxifen

MATOS, A. P.; PAPERNA, I.; LAINSON, R. An erythrocytic virus of the brazilian tree-frog, *Phrynohyas venulosa*. **Memórias do Instituto Oswaldo Cruz**, v. 90, n. 5, p. 653-655, 1995.

MATYJA, E.; TARASZEWSKA, A.; NAGANSKA, E.; RAFALOWSKA, J. Autophagic degeneration of motor neurons in a model of slow glutamate excitotoxicity *in vitro*. **Ultrastructural Pathology**, v. 29, n. 5, p. 331-339, 2005.

MIZUTANI, A.; OKADA, T.; SHIBUTANI, S.; SONODA, E.; HELFRID, H.; NISHIGORI, C.; MIYACHI, Y. B.; TAKEDA, S. A.; YAMAZOE, M. A. Extensive Chromosomal Breaks Are Induced by Tamoxifen and Estrogen in DNA Repair-Deficient Cells. **Cancer Research**, v. 64, n. 9, p. 3144-3147, 2004.

MORETTI, L.; YANG, E. S.; KIM, K. W.; LU, B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. **Drug Resistance Updates**, v. 10, n. 4-5, p. 135-143, 2007.

NYSTEDT, M.; BERGLUND, G.; BOLUND, C.; FORNANDER, T.; RUTQVIST, L. E. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. **American Journal of Clinical Oncology**, v. 21, n. 9, p. 1863-1844, 2003.

OGATA, A.; YANAGIE, H.; ISHIKAWA, E.; MORISHITA, Y.; MITSUI, S.; YAMASHITA, A.; HASUMI, K.; TAKAMOTO, S.; YAMASE, T.; ERIGUCHI, M. Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in *in vitro* and *in vivo* models. **British Journal of Cancer**, v. 98, n. 2, p. 399-409, 2008.

OMOTI, A. E.; OMOTI, C. E. Toxicidad ocular de la quimioterapia sistémica anticancerosa. **Pharmacy Practice**, v. 4, n. 2, p. 55-59, 2006.

OSBORNE, C. K.; ZHAO, H.; FUQUA, S. A. Selective estrogen receptor modulators: structure, function, and clinical use, **Journal of Clinical Oncology**, v. 18, n. 17, p. 3172-3186, 2000.

PAGLIARA, P.; CHIONNA, A.; PANZARINI, E.; DE LUCA, A.; CAFORIO, S.; SERRA, G.; ABBRO, L.; DINI, L. Lymphocytes apoptosis: young versus aged and humans versus rats. **Tissue and Cell**, v. 35, n. 1, p. 29-36, 2003.

PETINARI, L.; KOHN, L. K.; CARVALHO, J. E.; GENARI, S. C. Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation *in vitro*. **Cell Biology International**, v. 28, n. 7, p. 531-539, 2004.

QADIR, M. A.; KWOK, B.; DRAGOWSKA, W. H.; TO, K. H.; LE, D.; BALLY, M. B.; GORSKI, S. M. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. **Breast Cancer Research and Treatment**, v. 112, n. 3, p. 389-403, 2008. SARGENT, L. M.; DRAGAN, Y. P.; SATTLER, C.; BAHNUB, N.; SATTLER, G.; MARTIN, P.; CISNEROS, A.; MANN, J.; THORGEIRSSON, S.; JORDAN, V. C.; PILOT, H. C. Induction of hepatic aneuploidy *in vivo* by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. **Carcinogenesis**, v. 17, n. 5, p. 1051-1056, 1996.

SAWHNEY, R.; SEHL, M.; NAEIM, A. Physiologic aspects of aging: impact on cancer management and decision making, part I, **Cancer Journal**, v. 11, n. 6, p. 449-460, 2005.

SHAHI, P. K.; IZARZUGAZA PERÓN, Y.; ENCINAS GARCÍA, S.; DÍAZ MUÑOZ DE LA ESPADA, V. M.; PÉREZ MANGA, G. Tratamiento adyuvante en el cáncer de mama operable. **Anales de Medicina Interna**, v. 25, n. 1, p. 36-40, 2008.

STAHNKE, K.; FULDA, S.; FRIESEN, C.; STRAUB, G.; DEBATIN, K. M. Activation of apoptosis pathways in peripheral blood lymphocytes by *in vivo* chemotherapy. **Blood**, v. 98, n. 10, p. 3066-3073, 2001.

STYLES, J. A.; DAVIES, A.; DAVIES, R.; WHITE, I. N. H.; SMITH, L. L. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from doses rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). **Carcinogenesis**, v. 18, n. 2, p. 303-313, 1997.

STYLES, J. A.; DAVIES, R.; FENWICK, S.; WALKER, J.; WHITE, I. N. H.; SMITH, L. L. Tamoxifen mutagenesis and carcinogenesis in livers of lambda/lacI transgenic rats: Selective influence of phenobarbital promotion. **Cancer Letters**, v. 162, n. 1, p. 117-122, 2001.

WANG, C. W.; KLIONSKY, D. J. The molecular mechanism of autophagy. **Molecular Medicine**, v. 9, n. 3-4, p. 65-76, 2003.

WANG, L.; YU, C.; LU, Y.; HE, P.; GUO, J.; ZHANG, C.; SONG, Q.; MA, D.; SHI, T.; CHEN, Y. TMEM166, a novel transmembrane protein, regulates cell autophagy and apoptosis. **Apoptosis**, v. 12, n. 8, p. 1489-1502, 2007.

WHITE, I. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. **Current Drug Metabolism**, v. 4, n. 3, p. 223-239, 2003.

WOZNIAK, K.; KOLACINSKA, A.; BLASINSKA-MORAWIEC, M.; MORAWIEC-BAJDA, A.; MORAWIEC, Z.; ZADROZNY, M.; BLASIAK, J. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. **Archives of Toxicology**, v. 81, n. 7, p. 519-527, 2007.

Received on May 11, 2009. Accepted on July 28, 2009.

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.